A Chat with Anat

My guest for this special episode is Professor Paolo Lanzetta, Chair of the Department of Ophthalmology at the University of Udine, Italy. In this episode, Paolo and I explore the importance of monitoring the fellow eye of patients with nAMD. We also discuss methods and techniques for early detection of disease, the difference in monitoring for patients with DME, and the Vision Academy’s evidence-based guidance on monitoring the fellow eye. 

To learn more about monitoring the fellow eye in patients with nAMD, read the Vision Academy Viewpoint, the Vision Academy slide deck, and the Vision Academy publication on current concepts and modalities for monitoring the fellow eye in nAMD.  For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites.

If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! 

Speaker disclosures:

Professor Anat Loewenstein

Consultant: 4DMT, AbbVie, Astellas, Bayer, Beyeonics, Eyepoint, Notal Vision, Ocular Therapeutix, Ocuphire, Oculis, Opthea, Roche, Boehringer-Ingelheim, Aviceda, Voiant

Professor Paolo Lanzetta

Consultant: Aerie, Allergan, Apellis, Bausch + Lomb, Bayer, Biogen, Boehringer Ingelheim, I-Care, Genentech, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Roche

May 2025 | PP-PF-OPHT-ALL-0219-1

Further information on topics discussed in this podcast:

Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009 Jan;116(1):57─65.e5.

Chew JK, Zhu M, Broadhead GK, Luo K, Hong T, Chang AA. Bilateral Neovascular Age-Related Macular Degeneration: Comparisons between First and Second Eyes. Ophthalmologica. 2017 Jan 1;238(1-2):23–30.

Downey L, Acharya N, Devonport H, Gale R, Habib M, et al. Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era. BMJ Open Ophthalmol. 2021 Apr 27;6(1):e000696.

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419─31. 

Wong TY, Lanzetta P, Bandello F, Eldem B, Navarro R, Lövestam-Adrian M, et al. Current concepts and modalities for monitoring the fellow eye in neovascular age-related macular degeneration. Retina. 2020 Feb 4;40(4):599–611.

Zarranz-Ventura J, Liew G, Johnston RL, Xing W, Akerele T, McKibbin M, et al. The Neovascular Age-Related Macular Degeneration Database. Ophthalmology. 2014 Oct;121(10):1966–75.

This podcast series is intended for HCPs, and is not intended for UK audiences. 

Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.

This podcast series is produced and funded by Bayer Consumer Care AG. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer Consumer Care AG. The activities of the Barometer Program are funded and facilitated by Bayer Consumer Care AG where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.

The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer Consumer Care AG. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer Consumer Care AG.

My guest for this special episode is Prof. Jean- François Korobelnik from the Department of Ophthalmology at the University Hospital, and at CHU Bordeaux, in Bordeaux, France. In this episode, Jean-François and I explore the importance of choosing the right regimen for our patients with nAMD. We discuss the evidence we can gather from clinical trials, and the lessons we learn from patients we see during clinical practice. We also explore the algorithm developed by the Vision Academy to choose the best regimen for patients.

To learn more about how to choose the best treatment regimens to optimize outcomes for patients with nAMD, read the Vision Academy Viewpoint, and the accompanying slide deck. Please also visit the Vision Academy website. For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites.

If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! 

Speaker disclosures:

Professor Anat Loewenstein

Consultant: 4DMT, AbbVie, Astellas, Bayer, Beyeonics, Eyepoint, Notal Vision, Ocular Therapeutix, Ocuphire, Oculis, Opthea, Roche, Boehringer-Ingelheim, Aviceda, Voiant.

Professor Jean- François Korobelnik

Consultant: Abbvie, Adverum, Apellis, Bayer, Boehringer-Ingelheim, Carl Zeiss Meditec, Eyepoint Pharma, Ocular Therapeutix, Roche, SeaBeLife, Thea; member of the data safety monitoring board or advisory board for Alexion, Novo Nordisk, and Opthea.

April 2025 | PP-PF-OPHT-ALL-0215-1

Further information on topics discussed in this podcast:

Teo KYC, Eldem B, Joussen A, Koh A, Korobelnik JF, Li X, Loewenstein A, Lövestam-Adrian M, Navarro R, Okada AA, Pearce I, Rodríguez F, Wong D, Wu L, Zur D, Zarranz-Ventura J, Mitchell P, Chaudhary V, Lanzetta P. Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration. Eye (Lond). 2024. doi: 10.1038/s41433-024-03370-0. 

Gemenetzi M, Patel PJ. A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. Ophthalmol Ther. 2017;6:79-92. 

Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, McAllister IL, Essex RW, Morlet N, Gillies MC; Fight Retinal Blindness Study Group. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 2015;122:1212-9.

This podcast series is intended for HCPs, and is not intended for UK audiences. 

Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.

This podcast series is produced and funded by Bayer Consumer Care AG. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer Consumer Care AG. The activities of the Barometer Program are funded and facilitated by Bayer Consumer Care AG where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.

The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer Consumer Care AG. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer Consumer Care AG.

My guest for this special episode is Dr. John Kitchens, Vitreoretinal Surgeon with Retina Associates of Kentucky in the USA. In this episode, John and I explore the importance of holistic patient care. We also highlight the latest advances in home monitoring technologies in retinal disease, and how artificial intelligence (AI) can be used to aid in disease monitoring and optimization of clinic organization. 

To learn more about the current status of AI in screening, diagnosing and managing retinal diseases, read the Vision Academy Viewpoint, and the Vision Academy retinal expert consensuses by clicking here or here. For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites. If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! 

Speaker disclosures:

Professor Anat Loewenstein - Consultant: Consultant for 4DMT, Abbvie, Alkeus, Annexon, Apellis, Astellas, Bayer health care, Beyeonics, Eyepoint, J & J, NotalVision, Novartis, Ocular Therapeutics, Ocuphire Pharma, Ocuterra, Oculis, Opthea, Oxurion, Roche, Syneos.

Doctor John Kitchens - Consultant: Alcon, Allergan, Alimera, Apellis, Astellas, Bayer, Biogen, Bausch + Lomb, Genentech, Kodiak Bioscience, Notal Vision, Optos, Oculus, Outlook, Regeneron, Roche, and Zeiss. Speaker: Alcon, Bayer, Genentech, and Regeneron. Owns stock in Regeneron.

Further information on topics discussed in this podcast:

Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417–1436.

The Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, SanGiovanni JP, et al. Lutein/Zeaxanthin for the Treatment of Age-Related Cataract: AREDS2 Randomized Trial Report No. 4. JAMA Ophthalmol. 2013;131:843–850. 

Anguita R, Ferro Desideri L, Loewenstein A, et al. The digital age in retinal practice. Int J Retina Vitreous. 2024 Sep 26;10:67. doi: 10.1186/s40942-024-00580-2. 

January 2025 | PP-PF-OPHT-ALL-0199-1

This podcast series is intended for HCPs, and is not intended for UK audiences. 

Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.

This podcast series is produced and funded by Bayer Consumer Care AG. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer Consumer Care AG. The activities of the Barometer Program are funded and facilitated by Bayer Consumer Care AG where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.

The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer Consumer Care AG. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer Consumer Care AG.

My guest for this episode is Professor David Wong from the Department of Ophthalmology and Vision Sciences, University of Toronto and Unity Health Toronto in Toronto, Canada. In this episode, David and I discuss the Vision Academy’s algorithms for suspending treatment for nAMD in the context of treatment futility and success. 

Our conversation highlights the monitoring considerations and criteria used to define treatment futility and success, and the potential of predictive biomarkers and at-home monitoring to optimize patient follow-up. Important resources, such as the Vision Academy Viewpoint and algorithm on suspending treatment of nAMD in cases of futility, can be found on the website. Or can be downloaded directly from here; view point and slide deck. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. 

If you enjoyed this episode, SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here.

Speaker disclosures:

Professor Anat Loewenstein

Consultancy: 4DMT, Abbvie, Alkeus, Annexon, Apellis, Astellas, Bayer health care, Beyeonics, Eyepoint, J & J, NotalVision, Novartis, Ocular Therapeutics, Ocuphire Pharma, Ocuterra, Oculis, Opthea, Oxurion, Roche, Syneos.

Professor David Wong 

Consultancy: Abbvie, Alcon, Apellis, Bayer, Bausch Health, Biogen, Boehringer Ingelheim, Novartis, Ripple Therapeutics, Roche, Topcon, and Zeiss; Research grants: Novartis and Roche.

Further information on other studies mentioned in this episode:

Wong DT, et al. SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY. Retina. 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448759/ 

June 2026 | PP-PF-OPHT-ALL-0162-1

This podcast series is intended for HCPs, and is not intended for UK audiences. 

Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.

This podcast series is produced and funded by Bayer Consumer Care AG. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer Consumer Care AG. The activities of the Barometer Program are funded and facilitated by Bayer Consumer Care AG where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.

The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer Consumer Care AG. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer Consumer Care AG.

My guest for this special episode is Peter Holland, Chief Executive of the International Agency for the Prevention of Blindness (IAPB). We speak about the importance of World Sight Day, and discuss how different initiatives, such as the Love Your Eyes campaign, have helped put eye health on the global agenda in collaboration with members and partners.

We also highlight how clinicians can leverage their voices and influence to share knowledge, shape policies, and strengthen cross-sector collaborations, leading to the development of important resources for patients and clinicians to improve care. We recommend visiting the IAPB’s website, and the websites of the nAMD Barometer Program and Vision Academy for more information on World Sight Day, and resources to help you in your clinic. 

If you enjoyed this episode, SUBSCRIBE to ‘A Chat with Anat’ to make sure you never miss an episode! 

Speaker disclosures:

Professor Anat Loewenstein
Consultant: AbbVie, Bayer, Beyeonics, Syneos, Ripple, Iveric Bio, Johnson & Johnson, Ocuphire, Iqvia, Notal Vision, Novartis, and Roche.

Peter Holland
Employee: International Agency for the Prevention of Blindness.

Further information on topics discussed in this podcast:

Child eye health. The International Agency for the Prevention of Blindness. https://www.iapb.org/learn/vision-atlas/magnitude-and-projections/child-eye-health/. Accessed October 9, 2024.

June 2026 | PP-PFM-OPHT-ALL-0042-1

This podcast series is intended for HCPs, and is not intended for UK audiences. 

Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.

This podcast series is produced and funded by Bayer Consumer Care AG. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer Consumer Care AG. The activities of the Barometer Program are funded and facilitated by Bayer Consumer Care AG where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.

The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer Consumer Care AG. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer Consumer Care AG.

My guests for this episode are Professor Sobha Sivaprasad, Consultant Ophthalmologist at Moorfields Eye Hospital and Professor of Retinal Clinical Studies at the UCL Institute of Ophthalmology in London, and Professor Gemmy Cheung, Professor and Senior Consultant Ophthalmologist at the Singapore National Eye Centre, Duke-NUS Medical School, National University of Singapore. In this special episode, we discuss our experiences as women working in ophthalmology, and the advice we would give to young, aspiring ophthalmologists.

We also talk about what it meant to us to be named on The Ophthalmologist’s Power List, and how the next generation of ophthalmologists can be empowered through mentorship. We recommend visiting the Vision Academy Program website and nAMD Barometer Program website. We participate in these Programs to help develop important materials and training resources for clinicians and patients to improve patient-focused care and clinical practice.

If you enjoyed this episode, SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here.

Speaker disclosures:

Professor Anat Loewenstein

Consultancy: AbbVie, Bayer, Beyeonics, Syneos, Ripple, Iveric Bbio, Johnson & Johnson, Ocuphire, Iqvia, Notal Vision, Novartis, and Roche.

Professor Sobha Sivaprasad 

Consultancy: AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Phamaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics and Sanofi; Research grants: Bayer and Boehringer Ingleheim.

Professor Gemmy Cheung

Consultancy: Bayer, Roche, and Novartis.

June 2026 | PP-PF-OPHT-ALL-0164-1

This podcast series is intended for HCPs, and is not intended for UK audiences. 

Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.

This podcast series is produced and funded by Bayer Consumer Care AG. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer Consumer Care AG. The activities of the Barometer Program are funded and facilitated by Bayer Consumer Care AG where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.

The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer Consumer Care AG. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer Consumer Care AG.

In this episode, my guests Vision Academy and Barometer Program member Professor Jean-François Korobelnik, Professor and Head of the Ophthalmology Department at the University Hospital of Bordeaux in France, and Vision Academy member Professor Robyn Guymer, Deputy Director at the Centre for Eye Research and Professor of Ophthalmic at the University of Melbourne in Australia, discuss considerations for devising flexible and individualized treatment regimens for patients with nAMD with residual fluid.

Using examples from their own clinical experience, Professors Korobelnik and Guymer explore the nuanced relationship between efficacy of anti-VEGF treatment and location and presence (or absence) of fluid in patients with nAMD.

The Vision Academy Viewpoint providing recommendations for the assessment and monitoring of fluid status can be found on the website, along with other viewpoints and resources. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.

SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here.                    

Speaker disclosures:

Professor Jean-François Korobelnik 
Consultancy: Abbvie, Allergan, Apellis, Bayer, Carl Zeiss Meditec, Janssen, NanoRetina, Roche, and Théa.

Professor Robyn Guymer
Advisory boards and/or Consultancy: Apellis, Bayer, Belite Bio, Boehringer Ingelheim Pharmaceuticals, Character Bioscience, Genentech, Novartis, Ocular Therapeutix, and Roche.

March 2026 | PP-PF-OPHT-ALL-0161-1

Further information on residual fluid:

Arnold J.J, et al. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806513/

Lek JJ., et al. Interpretation of subretinal fluid using OCT in intermediate age-related macular  degeneration. Ophthalmol Retina. 2018. https://www.sciencedirect.com/science/article/abs/pii/S2468653017307315?via%3Dihub 

Hahn P, Eliott D, eds. 2021 Global Trends in Retina Survey. 2021. https://www.asrs.org/content/documents/2021-global-trends-survey-highlights.pdf (accessed 2 April 2024).

This podcast series is intended for HCPs, and is not intended for UK audiences. 

Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.

This podcast series is produced and funded by Bayer Consumer Care AG. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer Consumer Care AG. The activities of the Barometer Program are funded and facilitated by Bayer Consumer Care AG where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.

The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer Consumer Care AG. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer Consumer Care AG.

In this episode, Vision Academy members Professor Annabelle Okada, Professor of Ophthalmology and Director of the Ocular Inflammation Service and the Macular Disease Service at the Kyorin University School of Medicine in Japan, and Professor Ian Pearce, Consultant Ophthalmologist and Vitreoretinal Surgeon at the Royal Liverpool University Hospital in the UK, discuss the pachychoroid spectrum.

Using practical examples from their own clinics, they explore how accurate diagnosis, monitoring, prognosis and treatment decisions depend upon consensus descriptions of clinical, morphological and epidemiological characteristics disorders on the pachychoroid spectrum. They also discuss multimodal imaging and barriers to its implementation in clinical practice.

The Vision Academy Viewpoint covering the consensus on the definition of pachychoroid and details on the management of the pathologies included in this spectrum, and other important viewpoints and resources, can be found here. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.

If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing the importance of characterizing macular neovascularization subtypes in nAMD to optimize treatment outcomes, and how we as ophthalmologists can best choose the optimal anti-VEGF therapy regimen for our patients with retinal vascular diseases. SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!

Speaker disclosures:
Professor Annabelle Okada
Consultancy: Bayer, Chugai, Novartis, Roche, and Santen Pharmaceutical.

Professor Ian Pearce 
Consultancy: Apellis, Bayer, Novartis, and Roche.

March 2026 | PP-PF-OPHT-ALL-0160-1

Further information on Pachychoroid:

Castro-Navarro V., et al. Pachychoroid: current concepts on clinical features and pathogenesis. Graefes Arch Clin Exp Ophthalmol.2020. 

Warrow DJ., Hoang QV. and Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013. 

Miyake M., et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep. 2015.

Li Y., et al. Polypoidal choroidal vasculopathy in adult Chinese: the Beijing Eye Study. Ophthalmology. 2014. 

Li Y., et al. Prevalence and associations of central serous chorioretinopathy in elderly Chinese. The Beijing Eye Study 2011. Acta Ophthalmol. 2016. 

Manayath GJ., et al. Polypoidal choroidal vasculopathy associated with central serous chorioretinopathy: pachychoroid spectrum of diseases. Retina. 2018. 

This podcast series is intended for HCPs, and is not intended for UK audiences. 

Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.

This podcast series is produced and funded by Bayer Consumer Care AG. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer Consumer Care AG. The activities of the Barometer Program are funded and facilitated by Bayer Consumer Care AG where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.

The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer Consumer Care AG. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer Consumer Care AG.

My guest for this special episode recorded live at the 15th Annual Congress on Controversies in Ophthalmology (COPHy) is Professor Tariq Aslam, Professor of Ophthalmology and Interface Technologies at University of Manchester, United Kingdom.
 
In this episode, Tariq and I discuss whether the introduction of next generation therapies for the clinical management of retinal diseases will open the door to a new era for patients and clinicians.

We also consider how learnings from the Barometer Global Survey surrounding the multiple challenges associated with management of retinal diseases can be implemented into clinical practice, and touch on how we can best support our patients to achieve extended treatment intervals.

If you want to know more about the Barometer Program’s Global Survey, or the Barometer’s efforts towards patient-focused care, visit our website: https://www.amdbarometer.org/. Also on the website are important materials resources to help you in your clinical practice (such as communication guides and educational materials) and to help your patients (such as information packs for patients to give to their employers).

If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing how to choose the optimal anti-VEGF therapy regimen for patients with retinal vascular diseases, how patients’ emotions, experiences, and perceptions can influence their treatment adherence and persistence, and how we as ophthalmologists can both understand and help patients with the burden of treatment.

SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!

Further information on content in other podcasts in this series can be found at: https://www.amdbarometer.org/resources

This podcast was produced in association with the Vision Academy; viewpoints on clinically challenging situations, educational slide decks, video content and other materials, can be found at the Vision Academy, https://www.visionacademy.org/. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.

Speaker disclosures:

Professor Anat Loewenstein
Consultancy: Allergan, Annexon, Bayer, Beyeonics, Biogen, ForSight Labs, Iqvia, Iveric Bio, Johnson & Johnson, MJHEvents, Nanoretina, Notal Vision, Novartis, Ocuphire Pharma, Ocuterra, Ophtimedrx, Ripple Therapeutics, Roche, Syneos, WebMD, and Xbrane. 

Professor Tariq Aslam 
Grants/Speaker fees: Bayer, Canon, Heidelberg, Novartis, and Roche.

March 2026 | PP-PF-OPHT-ALL-0163-1

This podcast series is intended for HCPs, and is not intended for UK audiences. 

Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.

This podcast series is produced and funded by Bayer Consumer Care AG. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer Consumer Care AG. The activities of the Barometer Program are funded and facilitated by Bayer Consumer Care AG where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.

The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer Consumer Care AG. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer Consumer Care AG.

My guest for this episode is Professor Nicole Eter, Professor of Ophthalmology and Chair of the Department of Ophthalmology at the University of Münster, Germany. In this episode, Nicole and I chat about the different macular neovascularization (MNV) subtypes, discussing the diagnostic tools used to classify MNV subtypes, their defining characteristics and variants, and the impact of these on our patients.

Our conversation highlights why it’s important to tailor treatment to MNV subtype for our patients to have the best outcomes, and the significance of discussing lesions, prognoses and treatments with patients and their caregivers. Important resources, such as the Vision Academy Viewpoint on MNV subtypes and treatment algorithms and educational slide decks, can be found on the https://www.visionacademy.org/.  Or can be downloaded directly from here; view point and slide deck. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. 

If you enjoyed this episode, SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here at: https://www.amdbarometer.org/resources 

Speaker disclosures:
Professor Anat Loewenstein
Consultancy: Allergan, Annexon, Bayer, Beyeonics, Biogen, ForSight Labs, Iqvia, Iveric Bio, Johnson & Johnson, MJHEvents, Nanoretina, Notal Vision, Novartis, Ocuphire Pharma, Ocuterra, Ophtimedrx, Ripple Therapeutics, Roche, Syneos, WebMD, and Xbrane. 

Professor Nicole Eter 
Consultancy: Alcon, Allergan, Apellis, Bayer, Novartis, and Roche; Payments/honoraria: Allergan, Apellis, Bayer, Novartis, and Roche; Research grants: Bayer and Novartis; Support for meetings/travel: Roche.

March 2026 | PP-PF-OPHT-ALL-0159-1

Further information on other studies mentioned in this episode:
Mathis T, et al. Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. Eye. 2022. https://www.nature.com/articles/s41433-022-02231-y

Spaide RF, et al. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020. https://www.sciencedirect.com/science/article/pii/S0161642019322432

This podcast series is intended for HCPs, and is not intended for UK audiences. 

Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.

This podcast series is produced and funded by Bayer Consumer Care AG. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer Consumer Care AG. The activities of the Barometer Program are funded and facilitated by Bayer Consumer Care AG where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.

The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer Consumer Care AG. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer Consumer Care AG.